DJIA 17,719.92 -78.57 -0.44%
NASDAQ 5,108.67 -18.86 -0.37%
S&P 500 2,080.41 -9.70 -0.46%
market minute promo

Ophthotech (NASDAQ: OPHT)

63.57 0.65 (1.03%)

Quote as of

company name or ticker

Recent Quotes

OPHT $63.57 1.03%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $62.98
Previous Close $62.92
Daily Range $60.31 - $64.21
52-Week Range $35.72 - $72.51
Market Cap $2.2B
P/E Ratio -26.11
Dividend (Yield) $0.00 (0.0%)
Volume 494,158
Average Daily Volume 418,519
Current FY EPS -$3.45



Ophthotech (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website:

News & Commentary

Why Ophthotech Corporation's Shares Soared in October

A key clinical-stage development sparked enthusiasm for a next-generation treatment for age-related macular degeneration.

Today's Dead Cat Bounce Stock Is Ophthotech (OPHT)

3 Biotech Long Shots That Could Be Worth Betting On

There's no guarantee that these biotech stocks will overcome the long odds associated with drug development, but if they do, they could end up with top sellers on their hands.

3 Speculative Growth Stocks That Might Be Worth the Risk

Looking for a few growth stocks that could power your portfolio higher? Our contributors think these 3 names deserve a look.

3 Biotechs That Play Well with Others

Kindergarten teachers would be proud -- instead of battling to beat out their competitors, these companies are relying on a cooperative strategy that could benefit everyone involved -- including investors.

Relative Strength Alert For Ophthotech

Battleground: Will This $5 Biotech Stock Go To $22 Or $1.50?

Commit To Purchase Ophthotech Corp At $50, Earn 29.2% Annualized Using Options

What's Behind Ophthotech's Rapid Run Higher in July?

A chance for its clinical-stage drug Fovista to become a go-to vision therapy is sending shares higher.

Will Ophthotech (OPHT) Continue to Surge Higher? - Tale of the Tape

See More OPHT News...